Continuous biomanufacturing is considered the future phase for the optimization of production processes in the biopharmaceutical industry. Productivity, product quality and consistency are greatly improved while production costs and environmental footprint are drastically reduced. The manufacturing of monoclonal antibodies (mAbs), an important biopharmaceutical in the treatment of cancers, autoimmune disorders, and, more recently, COVID-19, is eligible for this continuous processing due to patent expiration and the subsequent need to lower manufacturing costs...